Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bim-22493
2. Imcivree
3. Rm-493
1. 920014-72-8
2. Rm-493
3. Bim-22493
4. Setmelanotide Acetate
5. N7t15v1fuy
6. (4r,7s,10s,13r,16s,19r,22r)-22-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1h-imidazol-5-ylmethyl)-7-(1h-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
7. 1504602-49-6
8. L-cysteinamide, N2-acetyl-l-arginyl-l-cysteinyl-d-alanyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-, Cyclic (2->8)-disulfide
9. Unii-n7t15v1fuy
10. Setmelanotide [usan:inn]
11. Setmelanotide [usan]
12. Setmelanotide (rm-493)
13. Setmelanotide [inn]
14. Setmelanotide [who-dd]
15. Gtpl9272
16. Chembl3301624
17. Schembl21840385
18. Ex-a5542
19. At23144
20. Cs-6399
21. Db11700
22. Irc-022493
23. Hy-19870
24. Q21098917
25. Rm-493; Bim-22493; Irc-022493
26. N2-acetyl-l-arginyl-l-cysteinyl-d-alanyl-l-histidyl-d-phenylalanyl-l-arginyl-l-tryptophyl-l-cysteinamide, Cyclic (2-8)-disulfide
| Molecular Weight | 1117.3 g/mol |
|---|---|
| Molecular Formula | C49H68N18O9S2 |
| XLogP3 | -2.5 |
| Hydrogen Bond Donor Count | 15 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 18 |
| Exact Mass | 1116.48580817 g/mol |
| Monoisotopic Mass | 1116.48580817 g/mol |
| Topological Polar Surface Area | 500 Ų |
| Heavy Atom Count | 78 |
| Formal Charge | 0 |
| Complexity | 2130 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Setmelanotide is indicated for chronic weight management in patients 6 years and older with obesity due to pro-opiomelanocortin deficiency, proprotein subtilisin/kexin type 1 deficiency, or leptin receptor deficiency. These conditions affect the MC4R signalling pathway.
Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.
Treatment of appetite and general nutrition disorders
Setmelanotide agonizes MC4R, downstream of multiple potential genetic deficiencies, to induce a feeling of satiety for chronic weight management. It has a moderate duration of action as it is given daily. Patients should be counselled regarding the risk of disturbances in sexual arousal, depression and suicidal ideation, and darkening of skin pigmentation. Exercise caution in neonates and low birth weight infants, as they may experience serious adverse effects due to benzyl alcohol.
A08AA
A - Alimentary tract and metabolism
A08 - Antiobesity preparations, excl. diet products
A08A - Antiobesity preparations, excl. diet products
A08AA - Centrally acting antiobesity products
A08AA12 - Setmelanotide
Absorption
Setmelanotide has a Tmax of 8 hours.
Route of Elimination
A 3mg subcutaneous dose of setmelanotide is 39% eliminated in the urine as the unchanged parent compound.
Volume of Distribution
The apparent volume of distribution of setmelanotide is 48.7 L.
Clearance
A 3mg subcutaneous dose of setmelanotide has an estimated clearance of 4.86 L/h.
Setmelanotide is expected to be metabolized to small peptides and amino acids.
The elimination had life of setmelanotide is approximately 11 hours.
Grehlin and other hunger signals from the gastrointestinal tract stimulate orexigenic neurons, stimulating the release of agouti-related protein. Agouti-related protein inhibits melanocortin 4 receptor (MC4R) activation until satiety signals such as insulin or leptin stimulate anorexigenic neurons. Insulin and leptin stimulate production of the POMC-derived melanocortin peptide -melanocyte simulating hormone, which is a ligand of MC4R. Orexigenic and anorexigenic neurons contain prohormone convertase 1/3 (PC1/3), which is encoded by the gene proprotein subtilisin/kexin type 1. PC1/3 preforms activation cleavage of a number of peptide hormone precursors, including -melanocyte simulating hormone. Setmelanotide is a pro-opiomelanocortin derived peptide that is an agonist of MC4R. It is an approximately 20-fold more potent agonist of MC4R than endogenous -melanocyte stimulating hormone, with an EC50 of 0.27 nM. By directly agonizing MC4R, upstream genetic deficiencies in the MC4R signalling pathway cannot inhibit satiety, food intake is decreased, and weight loss is achieved. MC4R is a 332 amino acid G-protein coupled receptor (G-PCR). Although the lack of cardiovascular adverse effects with setmelanotide treatment are not well understood, it is believed that earlier MC4R antagonists activated multiple G-protein signalling pathways. Earlier drugs that targeted G-PCRs either bound with high affinity to the highly conserved orthosteric binding site, or with high specificity to less conserved allosteric sites. Setmelanotide is an atypical bitopic ligand that interacts with both the orthosteric and putative allosteric binding site, allowing for both high affinity and specificity.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
